Followers | 826 |
Posts | 119567 |
Boards Moderated | 14 |
Alias Born | 09/05/2002 |
Friday, February 24, 2017 7:00:25 PM
https://www.sec.gov/Archives/edgar/data/1235010/000123501017000003/mnta1231201610k.htm#s8E0293C0D7E45268AB8DFF4D3C3CC319
The $485.6M pro forma cash consists of: $353.2M of unrestricted cash and marketable securities; $37.3M of net collaboration receivables from MYL relating to the companies’ FoB partnership; $21.8M of restricted cash (mostly relating to the Lovenox patent case); $51.2M received from SHPG in Jan 2017 pursuant to the termination of the M923 partnership (#msg-127579499); the $50.0M up-front amount payable by CSL for the autoimmune collaboration announced in Jan 2017 (#msg-127656306); less $27.9M in net accounts payable and deferred expenses.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM